The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts

References

• Angiolillo DJ The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 2012;72:2087–2116
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Jama 2002;288:2411–2420
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–1621
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179–1189
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505–1516
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–2273
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015;12:30–47
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Angiolillo DJ Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 2017;14:361–379
   PubMed Web of Science ®Google Scholar
• Bittl JA, Baber U, Bradley SM, et al. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1116–1139
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774–782.
   PubMed Web of Science ®Google Scholar
• Rao SV, O’Grady K, Pieper KS et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005;96:1200–1206
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Mehran R, Clayton TC et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2010;121:43–51
   PubMed Web of Science ®Google Scholar
• Mehran R, Pocock S, Nikolsky E et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011;4:654–664
   PubMed Web of Science ®Google Scholar
• Suh JW, Mehran R, Claessen BE et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2011;58:1750–1756
   PubMed Web of Science ®Google Scholar
• Genereux P, Giustino G, Witzenbichler B et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 2015;66:1036–1045
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Goto S Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010;31:17–28
   PubMed Web of Science ®Google Scholar
• Kato Y, Kita Y, Hirasawa-Taniyama Y et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 2003;473:163–169
   PubMed Web of Science ®Google Scholar
• Becker RC, Moliterno DJ, Jennings LK et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919–928
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404–1413
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366:20–33
   PubMed Web of Science ®Google Scholar
• Capodanno D, Alberts M, Angiolillo DJ Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol 2016;13:609–622
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis–task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087–1107
   PubMed Web of Science ®Google Scholar
• Moon JY, Nagaraju D, Franchi F et al. The role of oral anticoagulant therapy in patients with acute coronary syndrome. Ther Adv Hematol 2017; 204062071773369. [inpress].
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19.
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Windecker S, Vranckx P, et al. A critical appraisal of aspirin in secondary prevention: is less more? Circulation 2016;134:1881–1906
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet 1996;348:1329–1339
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Leadbeater PD, Chan MV et al. Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 2011;9:2103–2105
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ueno M, Goto S Basic principles of platelet biology and clinical implications. Circ J 2010;74:597–607
   PubMed Web of Science ®Google Scholar
• Dewilde WJM, Oirbans T, Verheugt FWA et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet 2013;381:1107–1115
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–2434
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513–1524
   PubMed Web of Science ®Google Scholar
• Ohman EM, Roe MT, Steg PG et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 2017;389:1799–1808
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Goodman SG, Bhatt DL et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update. Circ Cardiovasc Interv 2016;9 e004395
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017
   Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166
   PubMed Web of Science ®Google Scholar
• Yeh RW, Kereiakes DJ, Steg PG et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015;65:2211–2221
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–1800
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017 [Epub ahead of print]
   Google Scholar
• Levine GN, Bates ER, Bittl JA et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082–1115
   PubMed Web of Science ®Google Scholar
• Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340–1348
   PubMed Web of Science ®Google Scholar
• Colombo A, Chieffo A, Frasheri A et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086–2097
   PubMed Web of Science ®Google Scholar
• Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. Jama 2013;310:2510–2522
   PubMed Web of Science ®Google Scholar
• Schulz-Schupke S, Byrne RA, Ten Berg JM et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252–1263
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sabatine MS Oral dual antiplatelet therapy: what have we learnt from recent trials? Eur Heart J 2016;37:344–352
   PubMed Web of Science ®Google Scholar
• Yeh RW, Secemsky EA, Kereiakes DJ et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016;315:1735–1749
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025–1034
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Giustino G et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 2016;67:2224–2234
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ Tailoring duration of DAPT with risk scores. The Lancet 2017;389:987–989
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Windecker S et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention 2016;12:1239–1245
   PubMed Web of Science ®Google Scholar
• Baber U, Dangas G, Cohen DJ et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J 2016;182:125–134
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. Circulation. 2017 Oct 30. pii: CIRCULATIONAHA.117.031164. doi: 10.1161/CIRCULATIONAHA.117.031164. [Epub ahead of print] PMID: 29084738.
   Google Scholar
• De Luca L, D’Ascenzo F, Musumeci G et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention 2017;13:459–466
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017 [Epub ahead of print] 38 3070–3078
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Angiolillo DJ Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016;13:11–27
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017;390:1747–1757
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ Dual antiplatelet therapy guided by platelet function testing. Lancet 2017;390:1718–1720
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Denny JC, Lee CR et al. Prospective clinical implementation of CYP2C19-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in a real-world setting. Circulation 2016;134:e711–e712
   Web of Science ®Google Scholar
• Moon JY, Franchi F, Rollini F et al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol 2017:1–14
   PubMedGoogle Scholar